European Commission grants conditional marketing authorization to Pfizer's gene therapy, Durveqtix for adults with ...
Pfizer Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Durveqtix (fidanacogene elaparvovec), a gene therapy for the treatment of severe and moderately severe haemophilia B (congenital factor IX …